Health Economics›Melanoma›Metastatic or unresectable disease first-line

Metastatic or unresectable disease first-line

Melanoma · 19 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dacarbazine and Ipilimumab Variant #01	—	R 1 574 400	84d	—	11.2 mo	—	—	1
Ipilimumab monotherapy Variant #01	—	R 471 692	84d	4.4 mo	19.9 mo	2	R 943 384 PFS proxy	3
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	5.7 mo	39.5 mo	13	R 3 730 419 PFS proxy	4
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	11.5 mo	72.0 mo	9	R 707 538 PFS proxy	4
ABC Variant #01	—	R 75 758	28d	—	—	—	—	—
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #12	—	R 45 174	21d	4.8 mo	14.0 mo	7	R 316 220 PFS proxy	2
Temozolomide and Bevacizumab Variant #01	—	R 42 823	28d	—	—	—	—	—
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 38 912	21d	~5.7 mo	~13.9 mo	~9	~R 350 208 PFS proxy · indirect	11
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	3.0 mo	10.2 mo	5	R 25 154 PFS proxy	3
Cisplatin, Dacarbazine, Paclitaxel Variant #01	—	R 4 036	21d	—	—	—	—	—
Dacarbazine and Vindesine Variant #01 Partial	—	R 3 079	28d	—	—	—	—	—
CVD (Vinblastine) Variant #01	—	R 2 607	21d	—	—	—	—	—
Cisplatin and Dacarbazine Variant #01	—	R 2 346	21d	—	9.5 mo	—	—	1
Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine Variant #01 Partial	—	R 2 346	21d	—	11.0 mo	—	—	1
CVD (Vindesine) Variant #01 Partial	—	R 2 298	21d	—	12.0 mo	—	—	—
Dacarbazine monotherapy Variant #01	—	R 2 094	21d	2.5 mo	8.4 mo	4	R 8 376 PFS proxy	7
Nivolumab monotherapy Variant #01 Partial	—	—	14d	4.6 mo	34.1 mo	11	—	10
Nivolumab and Relatlimab Variant #01 Partial	—	—	28d	10.2 mo	52.2 mo	12	—	7
Fotemustine monotherapy Variant #01 Partial	—	—	56d	—	~13.8 mo	—	—	1

19 of 19 regimens shown